Research Library
Tesamorelin research
6 articles to explore, with links to 6 original sources.
About Tesamorelin
Tesamorelin is a modified analogue of growth hormone-releasing hormone used in receptor signaling research.
Explore study findings
What a randomized extension showed when participants switched to placebo
Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with an added chemical group at its starting end. An older clinical trial used a second randomized phase to ask what happened to abdominal visceral fat when participants continued the study treatment or switched to placebo.
2 sources (2010, 2026)
Check methods and identity
What the current U.S. label means by excess abdominal fat
Tesamorelin is a synthetic analogue of human growth hormone–releasing factor. It contains the 44-amino-acid sequence of that hormone and an added chemical group at the beginning. What does the approved indication mean when it describes a reduction in excess abdominal fat?
2 sources (2010, 2026)
What the TRIUMPH trial is designed to measure about physical function
Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with a chemical modification at its starting end. It can stimulate the pituitary to release growth hormone.
2 sources (2026)
What bioequivalence means in a comparison of tesamorelin formulations
Tesamorelin is a chemically modified 44-residue analogue of growth hormone–releasing hormone. A report published in January 2026 compared how the newer Egrifta WR formulation and the original Egrifta formulation appeared in the blood of healthy adults.
2 sources (2026)
What a liver-fat trial measured beyond abdominal fat
Tesamorelin is a chemically modified, 44-residue analogue of growth hormone–releasing hormone that stimulates the pituitary. An older trial asked whether the drug affected fat stored in the liver in adults with HIV and fatty liver disease.
2 sources (2019, 2026)
Interpret the evidence
Why a smaller waist did not establish improved cognition in an HIV trial
Tesamorelin is a 44-residue analogue of growth hormone–releasing hormone with a chemical group attached at its starting end. An older randomized trial asked whether tesamorelin changed thinking and memory measures in adults with HIV, abdominal obesity and neurocognitive impairment.
2 sources (2025, 2026)
